DLPIC
SAGE

Davide Leone & Partners Investment Company’s Sage Therapeutics SAGE Stock Holding History

Davide Leone & Partners Investment Company’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10,621
Closed -$795K – 102
2021
Q1 		$795K Buy
+10,621
New +$871K 0.1% 94

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Davide Leone & Partners Investment Company's SAGE Position: Q2 2021 in Review

Davide Leone & Partners Investment Company sold out of Sage Therapeutics (SAGE) in Q2 2021, closing a stake of 10,621 shares — an estimated $795K sold.

Davide Leone & Partners Investment Company first reported a position in SAGE in Q1 2021 and held it in 1 quarter. The position peaked at $795K in Q1 2021. 257 funds tracked by Wall St. Rank hold SAGE as of Q2 2021.

  • Davide Leone & Partners Investment Company reported no remaining Sage Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Davide Leone & Partners Investment Company sold 10,621 Sage Therapeutics shares in Q2 2021, an estimated $795K.
  • Davide Leone & Partners Investment Company first reported a position in Sage Therapeutics in Q1 2021 and held it in 1 quarter.
  • Davide Leone & Partners Investment Company's Sage Therapeutics position peaked at $795K in Q1 2021.
  • 257 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2021.

Based on Davide Leone & Partners Investment Company's 13F filing for Q2 2021, filed 16 Aug 2021.